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Feature
M
att Scott allows that he might not have been 
thinking too clearly that night in 1985 when the 
accident happened. After all, it was 2 A.M. when he 
and his friends returned home from a night of indulging 
in seasonal cheer, a few days before Christmas. That’s 
when someone thought it might be fun to blow up the old 
ﬁrecracker that had been sitting around the house since 
midsummer. “I happened to be the one to pick it up,” recalls 
Scott, then 24 and a paramedic. “I smoked at the time, and I 
was fooling around with my cigarette, touching the fuse to the 
tip of my cigarette, never expecting it to light. But it ignited 
pretty quickly, and burned even more quickly, ” he says. His 
friend screamed at him to throw it away. “But I just took two 
steps away from him into the kitchen, and it exploded.” 
The radial artery in Scott’s left arm was severed, splattering 
the kitchen wall with blood. Most of his left hand was gone. 
He clamped down on the injured limb with his other hand, 
thinking, “My career is over. My life is over. I can’t believe I 
did this.”
Scott and his surgeons decided that what remained of his 
left hand was not worth saving, so Scott agreed to amputation 
and was ﬁtted with a prosthesis. As it turned out, neither his 
career nor his life was over; Scott remained a ﬁeld paramedic 
for several years and adapted to the prosthesis. He married 
and had two sons. But eventually, he came to loathe the 
artiﬁcial hand. “It was a good prosthesis,” he says, “but it was 
cumbersome, it was uncomfortable, and it wasn’t ﬂesh and 
blood. It became odious to me.” 
When he read more than 10 years after his injury about a 
group of surgeons at Jewish Hospital in Louisville, Kentucky, 
who were planning to conduct a hand transplant despite 
widespread concern about the risks, Scott was intrigued and 
contacted the group. He ﬁt the criteria the surgeons were 
looking for: he had experienced the loss of his limb some 
time ago and although he learned to live with the prosthesis, 
his desire for a ﬂesh-and-blood replacement was strong 
enough that he was willing to take some signiﬁcant risks.
A Risky Proposition
In order to obtain a hand transplant from a genetically 
dissimilar individual, Scott had to agree to take a lifelong 
regimen of medications designed to suppress his immune 
system and prevent rejection of the grafted tissue (see Box 
1). But immunosuppressive drugs carry serious risks. They 
can disrupt immune surveillance—dampening the body’s 
main line of defense against infection and disease—and 
damage other body organs and systems. Hypertension, 
infection, tumors, and premature death are just some 
of the complications that can arise from the level of 
immunosuppression required for transplantation, says Warren 
Breidenbach, assistant clinical professor of surgery at the 
University of Louisville and the head of Scott’s transplant team. 
“The issue is always whether the risk is worth the beneﬁt.”
Such decisions are relatively clear-cut when forgoing a 
transplant means imminent death, as in the case of a heart 
transplant patient, or when the alternative means a drastically 
reduced quality of life, as in the case of a kidney patient who 
would otherwise face a life-long weekly dialysis regimen. (In 
such cases, organ availability is a much larger concern than 
immunosuppression.) The calculation for something like 
a hand transplant, however, is far more complicated;  the 
procedure can improve quality of life but cannot extend it. 
“Many patients would rather live with an amputation than 
accept the risk of a transplant,” says Breidenbach.
Solid organ transplants typically involve the transfer 
of a limited range of different tissue and cell types, but 
transplantation of a limb or other complex body structure, 
known as “composite tissue allotransplantation,” involves 
moving many different tissues, potentially including nerve, 
muscle, bone, and skin. Each tissue type involved in the 
transplant might provoke its own immune reaction in a 
recipient, explaining why limb transplantation was long 
considered impossible: the sheer variety of challenges it 
would present to the recipient’s immune system and the 
potentially deadly levels of immunosuppression needed 
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Transplantation of a limb or other 
complex body structure involves 
moving many different tissues, 
potentially including nerve, muscle, 
bone, and skin. Each tissue type might 
provoke its own immune reaction, 
explaining why limb transplantation 
was long considered impossible: 
the sheer variety of challenges it 
would present to the recipient’s 
immune system and the potentially 
deadly levels of immunosuppression 
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to overcome them appeared insurmountable. It wasn’t 
until the late 1990s that experiments conducted in animal 
models showed that the procedure could be viable and 
rejection could be prevented with the right combination of 
immunosuppressive drugs. 
Even so, when Scott was considering his hand transplant, the 
long-term risks and beneﬁts of the procedure were unknown. 
When he agreed to have the surgery done in January of 
1999, very few humans had undergone the procedure, so no 
one really knew how long immunosuppression would work, 
or whether a strong immune response to the graft might 
eventually overcome the drugs and cause rejection. The ﬁrst 
hand transplant patient, a New Zealand man named Clint 
Hallam, kept his new hand for only about 3 years. For some 
reason, Hallam ceased taking his immunosuppressive drugs. 
As a result, he started experiencing rejection and decided 
to have the transplanted limb amputated. Jean-Michel 
Dubernard, a clinician at the University of Lyons and head of 
Hallam’s transplant team, said the doctors watched helplessly 
as the hand’s function and appearance degraded. “Even at 
the time of amputation, pathological studies indicated the 
rejection may have been reversible if it were treated,” he says.
Yet even with complete compliance, doctors could offer no 
guarantees. Breidenbach says that in 1998, his team predicted 
that the odds were 50-50 that a transplanted hand would last 
1 year, and 1 in 4 that it would last 5 years. “And we were 
considered wildly optimistic,” he adds. Nonetheless, Scott, the 
ﬁrst patient in the United States to have the procedure done, 
has lived with his new hand for 9 years without incident, 
and other efforts have seen similar success.  For example, 
Dubernard’s group also worked on the ﬁrst double hand 
transplant recipient, whose grafts have survived more than 8 
years. By 2005, at least 18 patients worldwide had undergone 
single or double hand transplantation [1]. In America and 
Western Europe, the only cases where detailed information 
is available, no patients lost their transplanted limb as long 
as they remained compliant with the immunosuppressive 
drug regimen. Breidenbach says the success of hand 
transplantation has been “nothing less than shocking” to 
many in the medical community.
New Frontiers
Buoyed by the success, transplant doctors have moved on to 
other kinds of composite tissue transplantation [2] including, 
famously, the ﬁrst partial facial tissue transplant in 2004. The 
patient in that case, Isabelle Dinoire, had suffered severe 
facial trauma from an attack by her own dog. Dubernard, who 
treated Dinoire, says the attack destroyed her lips and much 
of the muscle on one side of her face. She could not speak 
clearly, could not eat or drink without a gastric tube, and was 
afraid to go out in public. 
A major goal of a facial tissue transplant is to cover the 
injury, which, depending on the severity or extent of the 
injury, is difﬁcult to achieve with reconstructive plastic 
surgery.  “In order to recover an entire face, we need about 
1,200 square centimeters of skin, and in the most ideal 
situation, pliable skin, in one piece,” says Maria Siemionow, 
whose team at the Cleveland Clinic is seeking to perform a 
similar face transplant procedure in the United States. The 
body can’t supply skin that meets these requirements.
As with hand transplants, facial tissue transplantation 
can involve the transfer and reattachment of skin, muscle, 
nerves, and sometimes bone. The recovery of sensory or 
motor nerve function can spell the difference between 
expressive and functional transplanted tissue and a mostly 
cosmetic improvement. In particular, whenever surgeons 
must reconnect a severed motor nerve, there is a risk of 
dyskinesia, where impaired motor nerve function prevents 
patients from controlling the expressivity of the transplanted 
tissue. These are just some of the issues (to say nothing of the 
host of psychological considerations) that need to be taken 
into account when deciding what kinds of injuries should be 
treated by transplantation.
Dinoire’s surgical team faced the considerable technical 
challenge of restoring motor function as well as sensory 
Box 1. Wrench in the Works
Any transplantation procedure between a genetically 
different donor and recipient carries the near-certainty that the 
recipient’s immune system will relentlessly attack the grafted 
tissue without the lifelong administration of potentially toxic 
immunosuppressive drugs. However, it’s somewhat ironic 
that the use of immunosuppressive drugs aims to hamstring 
a perfectly normal immune system that is doing just what 
evolution designed it to do: detect and respond to a foreign 
interloper.
By ignoring normal body structures while responding 
aggressively to the abnormal or unfamiliar, the immune system 
retains enough versatility to respond to pathogens or disease 
states like cancer while ignoring healthy tissues—except in rare 
cases of autoimmunity where a genetic error or environmental 
factors cause the immune system to attack the body. This 
arrangement poses a special challenge for tissue transplantation. 
That’s because although a donated organ, limb, or patch of skin 
may be absolutely healthy, it can still look like foreign matter to a 
recipient’s immune system if the donor is genetically different. 
Of special importance are genetic mismatches between blood 
groups (A, B, AB, or O) and between the donor’s and recipient’s 
complement of major histocompatibility complex (MHC) alleles 
(gene variants involved in alerting the immune system to the 
presence of foreign substances). Blood group differences imperil 
tissue transplantation, because pre-formed antibodies directed 
against the blood type determinants can provoke immediate 
and irreversible tissue rejection by attacking the vascular 
endothelium (called hyperacute rejection). A transplant cannot 
be performed when the recipient has high levels of antibodies 
to the donor’s blood group. Such blood group incompatibilities 
may impair the long-term survival of some kinds of organ 
transplants. Incompatibilities between the recipient’s and 
donor’s MHC gene variants can also provoke immune reactions 
to the graft, ranging from “acute rejection” in a matter of weeks, 
to “chronic rejection” years after transplantation. If pre-existing 
antibodies to the donor MHC molecules are detected before a 
transplant, then transplantation can’t be carried out. 
Usually only people within the same family—a recipient’s 
twin, sibling, or in rare cases, a parent—are likely to provide 
a matched set of MHC alleles. However, for most kinds of 
transplantation (with the prominent exception of bone marrow 
transplants), immune responses that would otherwise lead to 
graft rejection can be suppressed by a regimen of powerful 
immunosuppressive drugs, allowing patients to receive tissue 
transplants even from genetically different donors with ABO or 
MHC mismatches.PLoS Biology  |  www.plosbiology.org PLoS Biology  |  www.plosbiology.org 0426 March 2008  |  Volume 6  |  Issue 3  |  e70
function. They took a triangle of skin and muscle including 
nose and lips from a brain-dead donor and grafted it onto 
the injured site. Two years after the procedure, Dinoire has 
recovered enough sensitivity to feel heat, cold, and pressure 
in the grafted skin. She can also eat and speak more easily. A 
video accompanying the follow-up report on Dinoire’s surgery 
[3] shows her pronouncing difﬁcult phonemes, like “p” and 
“f”. Other recipients of composite tissue transplantation have 
experienced similar success with functional restoration of 
transplanted tissues. Scott says his transplanted left hand has 
achieved about 50% of the sensitivity and dexterity that he 
has in his right hand—a huge improvement over the limited 
functionality he had with the prosthesis.
Perhaps most importantly for both Scott and Dinoire, 
they can now go out in public without fear of ridicule. Just 
knowing that he has a ﬂesh-and-blood hand has made Scott 
happier and more conﬁdent in everyday life. “I was a master 
of hiding my prosthesis from people, greeting them in such a 
way that my body language would deﬂect their attention from 
looking at it,” he says. But that’s all in the past. “I don’t know 
how to explain it—but whatever dark cloud was in my soul is 
no longer there.”
Uncertain Future
For Scott, the beneﬁts of his procedure have been worth 
it, even though he went through some rough patches. He 
says the ﬁrst year was very unpleasant as his body adapted to 
the drugs, initially administered at very high levels. He also 
experienced two mild rejection episodes during the ﬁrst year 
while his doctors worked toward ﬁnding the right balance of 
immunosuppression. During his two rejection episodes, the 
hand’s skin grew red and looked blistered, but overall, the 
complications Scott experienced were relatively minor. 
Others haven’t been so lucky. For example, the Louisville 
group’s second hand transplantation patient experienced 
a condition called avascular necrosis, or bone death, 
from lost blood supply in the hip as a side-effect of his 
immunosuppressive drugs. The patient elected for hip-
replacement surgery rather than risk rejection of the hand 
from reducing immunosuppression. 
Dinoire also experienced several setbacks during the ﬁrst 
year, including two episodes of renal failure caused by her 
immunosuppressive drugs. Her doctors altered the types and 
amounts of drugs she was taking, and her kidney function has 
since recovered. But she’s also suffered other complications, 
including a herpes virus infection on her lips that may have 
triggered a rejection episode (see Figure 1). After a later 
rejection episode, she also developed a case of poxvirus 
infection on her graft and her own facial tissue.
What the future holds for these patients is unknown. Even 
with far more common and well-understood procedures 
such as kidney transplants, survival of grafted organs in 
the long term is threatened by eventual immune rejection. 
Transplantation specialists are eager to push the boundaries 
of medicine and science in an effort to improve the chances 
of graft survival and reduce the toxicity and morbidity of 
immunosuppressive drugs. While many research groups 
and pharmaceutical companies focus on developing more-
effective and less-toxic medications, others hope to eliminate 
immunosuppressive therapy altogether—some regard this 
prospect as the “Holy Grail” of transplantation biology.
“The generalized approach in transplantation for the 
last 50 years has been what I call ‘blindfolding the immune 
system,’” explains Jeffrey Bluestone, director of the Immune 
Tolerance Network. Bluestone says that steroids, calcineurin 
inhibitors, and similar drugs have all been designed to 
prevent the immune system from recognizing these foreign 
components. If immune cells can’t recognize a tissue as 
foreign, they can’t destroy it. But he says that the more 
innovative, and more difﬁcult, strategy involves reeducating 
the immune system, to somehow convince immune cells that 
the grafted tissue is not foreign. 
Many transplant groups are pursuing the possibility of 
persuading the immune system to see the grafted tissue as 
“self” and ignore it—to create a situation called “immune 
tolerance.” One current approach springs from experiments 
in animal models [4] that show that bone marrow from 
a transplant donor, when transferred to a recipient, can 
cause the recipient’s immune system to ignore the presence 
of other tissue transplants from the same donor. Such 
protocols have already been used in kidney transplants, 
allowing doctors to withdraw immunosuppression for some 
patients and yet retain functioning grafts [5,6], though many 
questions remain about potential side effects and the long-
term effectiveness of this strategy. Dubernard’s group also 
tried a related approach with Dinoire’s transplant by pre-
administering bone marrow–derived stem cells from the same 
doi:10.1371/journal.pbio.0060070.g001
Figure 1. Viral Infections Are a Common Side-Effect of 
Immunosuppression
An oral herpes, or cold sore, infection (causing sores like the one in the 
image on the left) on transplanted tissue triggered a rejection episode 
in the ﬁrst partial face transplant recipient.  Later, the patient suffered an 
outbreak of water warts (which are caused by the poxvirus Molluscum
contagiosum, pictured at right) on the transplanted tissue and her own 
skin as a consequence of the immunosuppressive regimen.
(Credits: Herpes image at left courtesy of Dr. Hermann at the Centers 
for Disease Control and Prevention, Atlanta, Georgia, United States. 
Molluscum image at right courtesy of Centers for Disease Control and 
Prevention)
In America and Western Europe, the 
only cases where detailed information 
is available, no patients have lost 
their transplanted limb as long as 
they remained compliant with the 
immunosuppressive drug regimen. 
The success of hand transplantation 
has been “nothing less than shocking” 
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donor who supplied the facial tissue. However, it is difﬁcult 
to tell whether there was any effect; Dinoire still experienced 
two episodes of acute rejection. Some variations of this 
procedure also carry a risk that elements of the transplanted 
bone marrow may attack the recipient—a life-threatening 
complication termed “graft versus host disease.” 
Another possible approach involves using new drugs to 
strengthen existing immune pathways, such as those that 
regulate inappropriate activity, to tamp down immune 
responses. For example, some groups are testing antibodies 
or chimeric molecules that bind certain cell surface molecules 
that transmit “shut-down” signals to immune cells. These 
signals cause immune cells to become dormant or to undergo 
cellular suicide, thus limiting an inappropriate (autoimmune) 
or undesired (transplant rejection) immune response [7].
Still another approach involves bolstering a population 
of regulatory immune cells that limit the intensity or 
duration of an immune response. For example, Bluestone’s 
research group is working with an antibody called anti-
CD3 that appears to promote expansion of this regulatory 
cell population.  This compound is already being tested in 
transplant settings. If it proves possible to direct the efforts 
of the regulatory immune cells speciﬁcally toward protecting 
transplanted tissue, clinicians could potentially prevent the 
rejection process from getting started—thus removing the 
need for immunosuppressive drugs by priming the patient’s 
own regulatory immune cells to protect the graft. However, 
such work is still in its early stages and few trials have been 
attempted in human subjects.
Philip Halloran, a prominent researcher on kidney 
transplantation at the University of Alberta, feels that none 
of the new approaches aimed at inducing immune tolerance 
are ready for clinical trials that involve the withdrawal of 
immunosuppression. For one thing, he worries that many 
of the protocols may not adequately target the antibody-
mediated pathways that cause the kind of chronic rejection 
that is observed in kidney transplants [8]. Additionally, 
he feels that other experimental protocols—particularly 
those involving bone marrow transplants—may pose 
unnecessary risks to patients. With so much yet to learn 
about the immunological pathways involved in rejection, 
Halloran argues that it’s too hard to predict whether 
individual patients might beneﬁt from such experimental 
protocols and it’s too risky to take transplant patients off 
immunosuppressive drugs. “How many of those patients will 
be able to go off immunosuppression and how many of them 
will undergo severe rejection to ﬁnd out they can’t come off 
immunosuppression? That’s very much an open question.”
In the end, it may prove impossible to completely 
eliminate risks to patients when it comes to something as 
complex as transplantation. However, regardless of the risks, 
someone will always be willing to push the boundaries in 
medicine and science. And patients like Scott and Dinoire—
and thousands of organ transplant patients—clearly 
demonstrate the need to do so. Although far fewer patients 
will beneﬁt from investments in transplant research than, 
say, cancer or cardiac-related diseases, Halloran makes the 
case that money invested in transplantation is money well 
spent. “It’s a lightweight in terms of patient numbers but a 
heavyweight in terms of the insights it generates for the rest 
of medicine.”
For more information on transplantation, go to http://
handtransplant.org/, http://immunetolerance.org/, or 
http://www.kidney.org/.  
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Transplantation specialists are 
eager to push the boundaries of 
medicine and science in an effort 
to improve the chances of graft 
survival and reduce the toxicity and 
morbidity of immunosuppressive 
drugs. Many research groups and 
pharmaceutical companies focus on 
developing more effective and less 
toxic medications; others hope to 
eliminate immunosuppressive therapy 
altogether—some regard this prospect 
as the “Holy Grail” of transplantation 
biology.